FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

10 letters match. Newest first.

  1. Amgen Inc.

    FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.

    Medium
  2. Stokes Healthcare Inc. dba Epicur Pharma

    FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.

    High risk
  3. Herbal Dermals LLC FZ dba Gotucream

    FDA warned Herbal Dermals LLC FZ dba Gotucream that its Gotucream balanitis cream is an unapproved new drug.

    Low
  4. Nexus Health Solutions LLC dba Harper Meds

    FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Low
  5. Thrivelab Co. dba Thrivelab

    FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.

    Medium
  6. Premium Health Management Inc. dba Premium Health

    FDA warns Premium Health over misleading website claims for compounded semaglutide and tirzepatide.

    Low
  7. 24HrDoc, Inc. dba 24HrDoc

    FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.

    Medium
  8. Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics

    FDA warned Deluxe IV and Aesthetics over misleading website claims for compounded semaglutide and tirzepatide, including implying FDA approval.

    Low
  9. ExThera Medical Corporation

    ExThera shipped Seraph 100 blood filters for compassionate use without FDA approval and promoted them as approved.

    High risk
  10. Elanco Animal Health USA

    FDA says Elanco's Pradalex ads misbrand the livestock antibiotic by claiming first-line use and "all relevant pathogen" coverage.

    Medium